betadex has been researched along with Asthma* in 2 studies
2 other study(ies) available for betadex and Asthma
Article | Year |
---|---|
Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.
To achieve an efficient lung delivery and efficacy, both active ingredient aerosolisation properties and permeability through the lung need to be optimized. To overcome these challenges, the present studies aim to develop cyclodextrin-based spray-dried microparticles containing a therapeutic corticosteroid (budesonide) that could be used to control airway inflammation associated with asthma. The complexation between budesonide and hydroxypropyl-β-cyclodextrin (HPBCD) has been investigated. Production of inhalation powders was carried out using a bi-fluid nozzle spray dryer and was optimized based on a design of experiments. Spray-dried microparticles display a specific "deflated-ball like shape" associated with an appropriate size for inhalation. Aerodynamic assessment show that the fine particle fraction was increased compared to a classical lactose-based budesonide formulation (44.05 vs 26.24%). Moreover, the budesonide permeability out of the lung was shown to be reduced in the presence of cyclodextrin complexes. The interest of this sustained budesonide release was evaluated in a mouse model of asthma. The anti-inflammatory effect was compared to a non-complexed budesonide formulation at the same concentration and attests the higher anti-inflammatory activity reach with the cyclodextrin-based formulation. This strategy could therefore be of particular interest for improving lung targeting while decreasing systemic side effects associated with high doses of corticosteroids. In conclusion, this works reports that cyclodextrins could be used in powder for inhalation, both for their abilities to improve active ingredient aerosolisation properties and further to their dissolution in lung fluid, to decrease permeability out of the lungs leading to an optimized activity profile. Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Inhalation; Aerosols; Animals; Asthma; beta-Cyclodextrins; Budesonide; Cells, Cultured; Drug Carriers; Humans; Lung; Male; Mice; Particle Size; Permeability; Powders; Solubility | 2015 |
A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma.
A new nanomedicine consisting of chitosan/carboxymethyl-β-cyclodextrin loaded with unfractioned or low-molecular-weight heparin is described and its potential in asthma treatment is evaluated. The nanoparticles are prepared by ionotropic gelation showing a size that between 221 and 729 nm with a positive zeta potential. The drug association efficiency is higher than 70%. Developed nanosystems are stable in Hank's balanced salt solution at pH = 6.4, releasing the drug slowly. Ex vivo assays show that nanocarriers lead to an improvement of heparin preventing mast cell degranulation. These results agree with the effective cellular internalization of the fluorescently labeled nanocarriers, and suggest these nanomedicines as promising formulations for asthma treatment. Topics: Animals; Asthma; beta-Cyclodextrins; Cell Degranulation; Cell Survival; Chitosan; Drug Carriers; Drug Compounding; Female; Heparin, Low-Molecular-Weight; Histamine; Histamine Release; Humans; Mast Cells; Molecular Weight; Nanomedicine; Particle Size; Rats; Rats, Sprague-Dawley; Spectrometry, Fluorescence | 2012 |